Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.58 |
| ▸ | CDK2 | P24941 | 8/20 | 0.58 |
| ▸ | CDK9 | P50750 | 8/20 | 0.58 |
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | FGR | P09769 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13727588 | 0.89 | TNNI3K (0.47) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL2462388 | 0.87 | CDK2 (0.57) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13726637 | 0.86 | TNNI3K (0.46) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13726586 | 0.86 | TNNI3K (0.46) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13726256 | 0.85 | CDK2 (0.43) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13726264 | 0.84 | TNNI3K (0.48) | CCNT1CCNE1CDK2CDK9CCNE2 | |
| SCHEMBL15463919 | 0.84 | CCNT1 (0.56) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13727475 | 0.83 | CDK2 (0.48) | CCNT1CCNE1CDK2CDK9CCNE2 | |
| SCHEMBL13727378 | 0.83 | CDK2 (0.42) | CCNT1CCNE1CDK2CDK9NEK2 | |
| SCHEMBL13723056 | 0.83 | CDK2 (0.47) | CCNT1CCNE1CDK2CDK9CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699554-B1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER IP GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2699554-B1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER IP GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8916557-B2 | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916557-B2 | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916557-B2 | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2699554-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | PAH, NAT1, H1-5 | CCNT1 28/4885CCNE1 57/4885CDK2 105/4885 |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | CCNT1 548/4885CCNE1 806/4885CDK2 56/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | CCNT1 236/4885CCNE1 357/4885CDK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.